Immune Checkpoint Inhibitors Market Size, Share, and Industry Analysis, By Target (PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors, and Others), By Indication (Lung Cancer, Melanoma, Renal Cell Carcinoma, Breast Cancer, GI Cancers, and Other Cancers), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, and Others), and Regional Forecast till 2034

The global immune checkpoint inhibitors market was valued at USD 55.00 billion in 2025. The market is projected to grow from USD 59.98 billion in 2026 to USD 120.00 billion by 2034, exhibiting a CAGR of 9.1% during the forecast period.

Immune checkpoint inhibitors form a potentially crucial part of the oncology market poised for significant expansion. Cancer treatment is moving toward immunotherapy-led and combination-based care. As more clinicians use PD-1, PD-L1, and CTLA-4 inhibitors across lung cancer, melanoma, bladder cancer, renal cancer, and several other solid tumors, demand keeps rising. The market growth is supported by the shift toward earlier lines of therapy, broader use in perioperative/adjuvant settings, and ongoing work on next-generation checkpoint combinations. Due to these factors, large pharmaceutical and biotechnology companies are increasing their strategic activity through licensing, collaborations, acquisitions, and targeted investments to strengthen pipeline depth and protect long-term market share.

• For instance, in March 2025, Sun Pharma acquired Checkpoint Therapeutics, adding UNLOXCYT (cosibelimab-ipdl), a PD-L1 checkpoint inhibitor, to its oncology portfolio. This deal highlighted how companies are using mergers and acquisitions to gain marketed immuno-oncology assets and strengthen their presence in skin cancer and broader oncology care.

Furthermore, funding initiatives, strategic partnerships, technological advancements, and new product launches by major companies strengthen their market position and support the global market growth.

Immune Checkpoint Inhibitors Market Driver

Increasing Use of Combination Immunotherapy Regimens to Accelerate Product Demand

The growing use of combination immunotherapy regimens is a major driver of the global market. Oncologists are seeking ways to improve response rates and extend survival beyond what single-agent therapy can deliver in many cancers. When checkpoint inhibitors are combined with other immunotherapies, chemotherapy, targeted therapy, or antibody-drug conjugates, they can produce broader and deeper clinical benefits across more tumor settings. These factors expand the eligible patient pool, support earlier-line treatment, and increase physician confidence in adopting these therapies more widely.

As more combination regimens show strong outcomes in late-stage trials and gain regulatory approvals, the demand for checkpoint inhibitors continues to rise across hospitals, cancer centers, and oncology networks.

• For instance, in November 2025, Merck & Co., Inc. received the approval from the U.S. FDA for KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX in combination with Padcev (enfortumab vedotin-ejfv) as perioperative treatment for adults with cisplatin-ineligible muscle-invasive bladder cancer.

Download Free sample to learn more about this report.

In 2026, the American Cancer Society estimated that 2,114,850 new cancer cases would occur in the U.S. alone. Among these, breast cancer and prostate cancer accounted for the major cases with an estimated 324,580 and 333,830 cases, respectively.

Immune Checkpoint Inhibitors Market Restraint

High Cost of Immune Checkpoint Inhibitor Therapy May Limit Treatment Access and Hamper Market Growth

The high cost of immune checkpoint inhibitors continues to be a key restraint on the growth of the market. These therapies place a heavy burden on payers, hospitals, and patients, especially when treatment duration is long or when drugs are used in combination regimens. As more checkpoint inhibitors move into earlier lines of therapy and broader cancer indications, the total treatment spending continues to rise, intensifying reimbursement scrutiny and slowing adoption in cost-sensitive markets. This creates a gap between clinical value and actual patient access, particularly in health systems that require strong cost-effectiveness evidence before funding new oncology drugs.

• For instance, in the NICE guidance last reviewed in March 2025, NICE said it was unable to make a recommendation on atezolizumab (Tecentriq) for untreated advanced or recurrent NSCLC in adults unsuitable for platinum-doublet chemotherapy because Roche did not provide an evidence submission. NICE states that Roche considered it unlikely that the evidence was sufficient to show that the technology is a cost-effective use of NHS resources in that population. Such instances demonstrate how cost-effectiveness concerns can directly limit access, even for an established checkpoint inhibitor.

Immune Checkpoint Inhibitors Market Opportunity

Development of Novel Bispecific and Multispecific Immuno-Oncology Agents Opening Future Growth Avenues

The development of novel bispecific and multispecific immuno-oncology agents is creating significant growth opportunities for the market globally. Since these therapies are designed to target multiple pathways simultaneously, they may be more effective at improving anti-tumor activity than traditional single-target checkpoint drugs. As the market becomes more competitive and many tumor types show limited response to standard PD-1 or PD-L1 monotherapy, drug developers are increasingly focusing on next-generation formats such as PD-1/VEGF, PD-1/IL-2, and other multi-target immune combinations. These factors can create opportunities to expand treatment benefits into harder-to-treat cancers, strengthen pipeline differentiation, and support premium commercial value in future launches. Due to this, bispecific and multispecific agents are opening an innovation cycle in immuno-oncology and giving companies more room to grow beyond the first wave of checkpoint inhibitor products.

• For instance, in June 2025, BioNTech and Bristol Myers Squibb announced a global strategic partnership to co-develop and co-commercialize BNT327, a PD-L1 x VEGF-A bispecific antibody, across multiple solid tumor types. The BNT327 is a clinically advanced investigational immunotherapy candidate and they plan to run a broad development program across numerous solid tumors. This shows how next-generation bispecific checkpoint approaches are creating future market expansion opportunities.

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence of Key Diseases, By Key Regions,2025
• Overview of Regulatory Scenario, By Key Regions/Countries
• Key Industry Developments (Strategic Collaborations, Acquisitions, and Mergers)
• New Product Launches, By Key Players
• Pipeline Analysis, By Key Players
• Key Startups, By Key Regions

Analysis by Target

Based on target, the global immune checkpoint inhibitor market is segmented into PD-1 inhibitors, PD-L1 inhibitors, CTLA-4 inhibitors, and others.

The PD-1 inhibitors segment dominates the market as they have the broadest clinical adoption across major solid tumors and robust commercial presence among checkpoint classes. As these drugs have gained approvals across lung cancer, melanoma, renal cell carcinoma, GI cancers, gynecologic cancers, and earlier-stage settings, physicians have become more comfortable using them across a wider patient pool. This wider label reach increases prescription volume, strengthens guideline inclusion, and gives PD-1 a clear advantage over narrower or earlier-stage checkpoint categories. Recent approvals in this category reinforce segmental growth.

• For instance, in February 2026, Merck & Co., Inc. announced that the U.S. FDA approved KEYTRUDA and KEYTRUDA QLEX in combination with paclitaxel with or without bevacizumab for certain adults with PD-L1-positive platinum-resistant ovarian carcinoma as second- or third-line treatment.

Analysis by Indication

Based on Indication, the global market is segmented into lung cancer, melanoma, renal cell carcinoma, breast cancer, GI cancers, and other cancers.

The lung cancer segment is anticipated to hold a significant market share. It represents one of the largest global cancer populations and has become one of the most established treatment areas for checkpoint inhibitors. As immune checkpoint inhibitors are used in metastatic, neoadjuvant, perioperative, and adjuvant settings for lung cancer, the number of eligible patients has expanded significantly. Such broad use across disease stages increases treatment volumes and keeps lung cancer at the center of clinical development and commercial activity for checkpoint therapies.

• For instance, in May 2025, Bristol Myers Squibb received approval from the European Commission for perioperative Opdivo plus chemotherapy, followed by adjuvant Opdivo, for adults with resectable, high-risk non-small cell lung cancer with PD-L1 expression of at least 1%.

Analysis by Distribution Channel

Based on distribution channel, the market is segmented into hospital pharmacies, specialty pharmacies, and others.

The hospital pharmacies segment is expected to dominate the market. Most immune checkpoint inhibitors are high-cost oncology biologics that are initiated, dispensed, and monitored through hospital-based cancer care systems. These products often require specialist handling, infusion-center coordination or supervised administration, reimbursement support, and close monitoring for immune-related adverse events. As a result, hospitals remain the main point of treatment delivery for many checkpoint regimens, especially in solid tumor care.

• For instance, in September 2025, Merck announced the U.S. FDA approval of KEYTRUDA QLEX, describing it as the first and only subcutaneously administered immune checkpoint inhibitor that can be administered by a healthcare provider in as little as 1 minute across most solid tumor indications for KEYTRUDA.

Regional Analysis

Request for Customization   to gain extensive market insights.

On the basis of region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America dominated with approximately 40.0% of the global immune checkpoint inhibitors market in 2025. The dominance of the region is due to a high cancer burden with early adoption of new oncology treatments, strong biomarker testing infrastructure, and faster uptake of checkpoint inhibitors in first-line and earlier-stage care. As more checkpoint therapies gain U.S. FDA approvals across additional tumor types and treatment settings, oncologists can use these drugs in a broader patient population, increasing treatment volume and supporting steady market expansion. North America also benefits from deep clinical trial activity and rapid commercialization of new formulations, which helps maintain high use of immune checkpoint inhibitors in routine cancer care.

• For instance, in March 2026, Bristol Myers Squibb received expanded U.S. FDA approval for Opdivo in classical Hodgkin lymphoma, including approval with AVD for previously untreated Stage III or IV disease. The development combined approved products in the U.S. for adult and pediatric patients 12 years and older with previously untreated advanced cHL, showing how continued label expansion is supporting regional market growth.

The Europe market is expected to grow at a significant CAGR during the forecast period. The market is growing in Europe as cancer remains a major public health burden across the region, while regulatory approvals are steadily broadening access to checkpoint inhibitors in new indications and more convenient delivery formats. As European health systems adopt more perioperative, adjuvant, and combination immunotherapy approaches, checkpoint inhibitors are being used in a larger share of oncology treatment pathways. This improves clinical integration, strengthens physician confidence, and supports higher demand across major European markets.

• For instance, in May 2025, Bristol Myers Squibb announced that the European Commission approved the subcutaneous formulation of Opdivo across multiple solid tumor indications. The development created the first PD-1 inhibitor with both intravenous and subcutaneous options in the EU, which can improve treatment convenience and help expand checkpoint inhibitor use across European oncology settings.

The Asia Pacific market is expected to grow at a stable CAGR during the forecast period. The market is growing in the Asia Pacific as the region has a large and still-rising cancer patient population, while countries such as China and Japan are rapidly expanding oncology research, local drug development, and checkpoint-based combination trials. This is making Asia Pacific both a high-demand treatment market and a major innovation hub for future growth in checkpoint inhibitors. These factors also encourage key companies to participate in strategic collaborations and monetize growth.

• For instance, in June 2025, Akeso announced that its PD-1/CTLA-4 bispecific antibody, cadonilimab, was approved in China for first-line treatment of cervical cancer in all-comer populations. The candidate became the third approved indication for cadonilimab, highlighting how locally developed checkpoint-based products are expanding the region’s treatment landscape and supporting market growth.

Key Players Covered

The global immune checkpoint inhibitors market is consolidated, with a few players capturing significant market share.

The report includes the profiles of the following key players.

• Merck & Co., Inc. (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• Hoffmann-La Roche Ltd (Switzerland)
• AstraZeneca PLC (U.K.)
• Regeneron Pharmaceuticals, Inc (U.S.)
• GSK plc (U.K.)
• BeiGene, Ltd. (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Shanghai Junshi Biosciences Co., Ltd (China)

Key Industry Developments

• February 2026: ImmunityBio, Inc., partnered with Biopharma and Cigalah, two respected healthcare commercial and distribution companies in the Middle East, to launch ANKTIVA (nogapendekin alfa inbakicept) in Saudi Arabia and, over time, across the broader MENA region.
• June 2025: Exelixis, Inc. announced positive topline results from the STELLAR-303 phase 3 pivotal trial in which zanzalintinib in combination with atezolizumab. These topline findings were from the final analysis conducted by the Independent Data Monitoring Committee of one of the dual primary endpoints of the STELLAR-303 phase 3 trial.